

ANALYSIS OF THE RESULTS OF TREATMENT OF 93 PATIENTS WITH POST-COVID THROMBOSES OF THE CAVERNOUS SINUS IN THE CONDITIONS OF THE DEPARTMENT OF PURULENT SURGERY

**Ulugbek K. Kasimov¹, Ulugbek P. Abdullaev², Kakhramon X. Boboev³,
Diyora U. Sultanova⁴**

1 Associate Professor, Department of General and Pediatric Surgery No. 1,
Tashkent medical academy, Uzbekistan
E-mail: kas-ulug@mail.ru

2 Assistant, Department of Otolaryngology and Dentistry,
Tashkent Medical Academy, Uzbekistan
E-mail: abdullayevulugbek1982@gmail.com

3 Assistant, Department of General and Pediatric Surgery No. 1,
Tashkent Medical Academy, Uzbekistan

4 Student of the medical and pedagogical faculty of
Tashkent Medical Academy, Uzbekistan
E-mail: diyora.kasimova.1999@mail.ru

ABSTRACT

Speaking of post-covid complications, the development of cavernous sinus thrombosis, which is a single cerebral vein and sinus thrombosis, with the development of a characteristic clinical syndrome, is alarming. There is an increase in the growth of this type of complication. In patients with COVID-19, the starting point is the presence and progression of fungal microflora, which manifests itself as rhino-orbital mucormycosis - ROM. Specialists faced the problem of managing these patients, which consists in late diagnosis and a corresponding high mortality rate. A number of unresolved issues have been identified, these are the causes and timing of the development of cavernous sinus thrombosis, criteria for the risk of development, determination of conservative and surgical tactics.

Key words: COVID-19; SARS-CoV-2; invasive mucormycosis; rhino-sino-orbital mucormycosis; diabetes; cavernous sinus thrombosis; infection; treatment

INTRODUCTION

Humanity faced a new challenge when, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of an outbreak of pneumonia cases in Wuhan, a city in the Chinese province of

Hubei. In the first few months of 2020, infection with this new coronavirus led to a global pandemic that affected every country in the world, with more than 21 million cases by August 2020 [1]. Although coronavirus disease 2019 (COVID-19) primarily presents as a lung infection with symptoms ranging from mild upper respiratory infection to severe pneumonia and acute respiratory distress syndrome, other multisystem manifestations of the disease and its associated complications are increasingly common. [2, 3]. Speaking of post-COVID complications, the development of thrombosis of the cavernous sinuses is alarming. Cavernous sinus thrombosis (CST) is a single cerebral vein and sinus thrombosis that causes a characteristic clinical syndrome. It usually has an infectious cause. Cavernous sinus thrombosis is a rare disease, although the exact frequency of its occurrence is unclear. The incidence of cerebral vein thrombosis is 13 cases per 1,000,000 per year [4]. Cavernous sinus is the least frequent localization of cerebral vein thrombosis [5,6]. Moreover, in the pre-antibiotic period, it was accompanied by high mortality [7]. The outcome of this condition has greatly improved since the advent and widespread use of antibiotics, but it still depends on timely diagnosis and treatment. Possible treatments include antibiotics, anticoagulants, and corticosteroids, as well as surgical treatment of the infection [8]. On the one hand, the main cause of cavernous sinus thrombosis may be a remote focus with sepsis, which can lead to cavernous sinus thrombosis. On the other hand, the infection can spread from the facial areas through the facial venous vessels and ophthalmic veins or from the sphenoid sinus directly into the adjacent cavernous sinus [9]. Among the most common causes contributing to this condition are nasal furuncle (50%), accompanied by ethmoid or sphenoid sinuses (30%) and dental infections (10%) [10,11]. The tonsils, soft palate, middle ear, mastoid process, and orbit are some of the most common major areas of infection. The venous system of the paranasal sinuses with a high degree of anastomosis allows the infection to spread retrogradely into the cavernous sinus through the superior and inferior ophthalmic veins [12,13]. And if earlier bacteria dominated in the etiology of cavernous sinus thrombosis, then in patients with COVID-19, the starting point is the presence and progression of fungal microflora, which manifests itself as rhino-orbital mucormycosis - ROM. ROM is the most common presentation, causing approximately two-thirds of all cases of mucormycosis [14,15]. The spores enter the nasopharynx, and tissue invasion, thrombosis, and necrosis progress from the nose to the cavernous sinuses. Pre-pandemic prevalence was estimated at 0.005–1.7 per million population worldwide [16, 17]. In COVID-19, the incidence of secondary bacterial or fungal infections is 8%, with aspergillosis and candida being the most common fungi [18, 19]. The current wave of COVID-19 has caused a

surge in mucormycosis. COVID-19 creates a hypoxic environment with high glucose, high ferritin, and reduced leukocyte phagocytic activity due to immunosuppression by the virus itself and the corticosteroids used in treatment. Such an environment is very conducive to the germination and reproduction of fungal spores [16]. Unhygienic practices, prolonged hospital stay with the possibility of nosocomial infection, use of immunosuppressants, and comorbidities are other risk factors associated with an increase in the incidence of COVID-19-associated ROM. According to published data, 76% of patients with COVID-19 associated rhino-sino-orbital mucormycosis were given a history of systemic corticosteroids [16]. Irrational or thoughtless use of corticosteroids may be a possible cause of ROM. Corticosteroids have been criticized for their role in increasing susceptibility to mucormycosis, and this claim is not entirely unfounded. A cumulative dose in excess of 600 mg of prednisone and 2–7 g of methylprednisolone has been found to predispose immunocompromised patients to mucormycosis [20]. Long-term administration of high doses of systemic corticosteroids for more than 3 weeks is considered a risk factor for the development of mucormycosis [21]. Literature Review of Existing Global Data Singh et al. [16] and Hoenigl et al. [22] showed that rhino-orbital mucormycosis develops in 80% of cases in patients with diabetes mellitus.

Summing up this review, a number of questions remain unresolved, in particular, in what terms the development of cavernous sinus thrombosis is possible and what is the starting point, where patients with this pathology should be treated and the criteria for their recovery.

The purpose of this work was to analyze the results of treatment of patients with cavernous sinus thrombosis in conditions of purulent surgery, with the definition of tactics for their treatment.

Research methods. Due to the increase in the number of patients with post-COVID complications, in particular, thrombosis of the cavernous sinuses, on August 28, 2021, under No. multidisciplinary TMA clinic, in the surgical block of specialized beds for patients with various manifestations of cavernous sinus thrombosis. The beds were created in the department of the Center for Purulent Surgery and Surgical Complications of Diabetes Mellitus, where 93 patients were treated from September to December.

In all patients, the clinical picture developed after suffering SARS-CoV-2, while we conditionally divided the patients into anatomical zones.

Table No. 1

Distribution of patients

Nosology	Total	
	n	%
TCS, with eye damage	26	27,9
TCS, with sinus damage	34	36,6
TCS, with the defeat of the maxillofacial area	33	35,5
Total	93	100

The analysis showed that an isolated lesion of one anatomical region was not observed in patients, mainly a combined lesion dominated, however, we divided the patients according to prevailing signs. Most often, patients had damage to the paranasal sinuses and maxillofacial region, which was detected in 36.6% and 35.5% of cases, respectively. At the same time, the involvement of the eyes in the process was manifested by the orbital fissure syndrome, manifested by ophthalmoplegia, ptosis, exophthalmos and enophthalmos, of varying severity. It was detected in 26 patients (27.9%). The distribution of patients by sex and age showed that the incidence in males and females was almost the same, amounting to 53.7% and 46.3%, respectively (Table No. 2). The average age of the patients was 56.1 ± 3.8 and I would like to note that patients of working age and the elderly prevailed. Thus, 39.8% of patients were aged 51-60 years old and 33.3% - 61-70 years old. See table No. 2.

Table No. 2

Distribution of patients by age and sex

Groups		Number of patients (n=93)	
		n	%
Age groups	up to 30 years	1	1,1
	31-40 years	7	7,5
	41-50 years	9	9,7
	51-60 years	37	39,8
	61-70 years	31	33,3
	71-80 years	7	7,5
	over 80 years	1	1,1
Average age, years		56,1±3,8	
Sex	male	50	53,7
	female	43	46,3

A study of the nature of the appealability of patients showed that the main contingent were patients from Tashkent - 11 and Tashkent region - 21. Patients from Namangan and Surkhondaryya regions also prevailed, which accounted for 11.8% and 13.9%. All patients were secondary, i.e. at the initial stage, they were treated at the place of stay (lost time) and only when the clinical picture worsened, they were sent to the TMA clinic (see table No. 3).

Table No. 3

Distribution of patients by regions.

Regions	Main	
	n	%
Tashkent	11	11,8
Tashkent region	21	22,6
Andijan region	4	4,3
Jizzakh region	5	5,4
Kashkadarya region	5	5,4
Navoi region	1	1,1
Namangan region	11	11,8
Samarkand region	5	5,4
Surkhondaryya region	13	13,9
Sirdarya region	8	8,6
Fergana region	7	7,5
Khorezm region	2	2,2
Total	93	100

After analyzing the timing of the appearance of the clinical picture of thrombosis of the cavernous sinuses after suffering COVID 19, it was revealed that they most often manifest themselves in terms of 7 to 14 days, in our study, there were 63 such patients, which is 67.7%, in second place is the manifestation occurred after 14 days, accounting for 20.4%. Less commonly, clinical manifestations occur up to 7 days after suffering COVID 19.

Table No. 4

Characteristics of patients by terms of hospitalization after suffering COVID

Time of treatment before hospitalization	Total	
	n	%
up to 7 days	11	11,9
7 – 14 days	63	67,7
over 14 days	19	20,4
Total	93	100

Taking into account the main contingent of patients, which was represented by patients of working age and the elderly, we analyzed the presence of comorbidities in these patients. 81.7% of patients had a history of diabetes mellitus, while they had type II diabetes mellitus and all of them received insulin, of various durations of action. In 59 patients (63.4%), hypertension was diagnosed and in 48.4% of cases, patients had coronary heart disease. See table No. 5.

table No. 5

Presence of comorbidities

Pathology	n	%
Diabetes	76	81,7
Hypertonic disease	59	63,4
Cardiac ischemia	45	48,4

The manifestation of clinical signs and the main complaints of patients were as follows. Almost all patients had headaches and nasal congestion of varying severity, which was in 84 patients (90%), in second place was the presence of sinus necrosis, in our patients it was in 76% of cases (71 patients). Necrosis of the upper palate was in 19 patients, and the intensity of necrosis at the time of treatment in patients was different, from the initial, in the form of limited cyanosis, to the formed one. At the same time, patients did not have limited necrosis (the presence of a demarcation line). Manifestations of the orbital fissure syndrome, such as visual impairment, ophthalmoplegia, diplopia, ptosis, exophthalmos were observed in 28 patients, which is 30%. See table No. 5

Table No. 5

The incidence of rhino-cerebral complications

№	Complications	n	%
1	Necrosis of the nasal mucosa and paranasal sinuses	71	76,3
2	Eye complications	61	65,6
3	Meningeal complications	20	21,5
4	Cerebral circulation disorders	9	9,6

The study of the development of rhino-sino-cerebral complications of cavernous sinus thrombosis showed that 71 patients had necrosis of the nasal mucosa and paranasal sinuses, 65.6% had ocular complications of varying severity, and 9.6% of patients had cerebrovascular accidents (table number 6).

The tactics of medical and diagnostic measures included multislice computed tomography, taking clinical and laboratory tests and surgical intervention. The

choice of tactics of surgical treatment included FESS - functional endoscopic sinus surgery, the volume of which was different See table No. 7.

Table No. 7

The nature and number of operations performed

Type of operation	n	%
Necrectomy	4	4,3
Maxillary sinusectomy + necrectomy	29	31,2
Sequestrectomy	10	10,6
Opening of soft tissue abscess	2	2,2
Puncture of the maxillary sinus	1	1,1
Cancellation of the operation	2	2,2
Without surgery	45	48,4
Total	93	100

As can be seen from the presented table, surgical interventions of a different nature were performed in half of the treated patients. In 31.2% of cases sinustomy with necrectomy was performed, in 10 (10.6%) patients sequestrectomy was performed. Against the background of the development of necrotic manifestations of the nasal mucosa in 2 patients, the process progressed with the transition to the face and the development of phlegmon of the facial area. In the presence of clear indications for surgical intervention, two patients refused operations. 48.4% of patients did not undergo surgical interventions. The reasons for their failure were the severity of the condition of the patients, the extent of the lesion and the refusal of relatives to perform the operation. This indicator is also reflected in the results of treatment..

Table No. 8

Distribution of patients depending on the results of treatment.

Results	n	%
Discharged for outpatient treatment	29	31,2
Transferred to another medical institution	2	2,1
Because of severe condition was taken to home	62	66,7
Total	93	100

Analyzing the results of treatment of patients, it can be seen that only in 31.2% of cases, patients were discharged with positive dynamics for further treatment and observation on an outpatient basis, and while more than half of the patients 62 (66.7%) were taken home. The reasons for this were the serious condition of the patients, the refusal to perform surgery, the deterioration of the condition after the surgical operation. Two patients were transferred to the Department of Neurology due to the progression of the clinical picture of acute cerebrovascular accident.

Thus, the study showed that it is necessary to revise the tactics of diagnosis and management of patients with post-COVID manifestations of cavernous sinus thrombosis. It would seem that the stopped state of acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) gives a formidable complication in the form of thrombosis of the cavernous sinuses with rhino-orbital mucormycosis. In our opinion, an in-depth study of this pathology is necessary, with the development of guidelines for the early detection and management of such patients, the determination of the dominant specialists in whose department these patients should be located in order to exclude the development of cross-infection. Recommendations should reflect specific criteria for when expectant management is needed, and when emergency surgery is needed, because. Another outbreak of the virus with its new mutating strains is not excluded, where specialists should be ready to manage these patients.

REFERENCES

1. Aghagoli G., Gallo Marin B., Soliman LB, Sellke FW. Cardiac injury in patients with COVID-19: risk factors, predictors, and complications: a review. *J Card Surg.* 2020; 35 (6): 1302–1305.;
2. Cerebral venous thrombosis. Silvis S.M., de Souza D.A., Ferro J.M., Coutinho J.M. *Nat Rev Neurol.* 2017 Sep; 13 (9): 555-565.;
3. Connors JM, Levy JH. Thrombus inflammation and COVID-19 hypercoagulability. *J Thromb Haemost.* 2020; 18(7): 1559–1561.;
4. Endoscopic marsupialization of the mucocele of the lateral frontal sinus with orbit expansion: a clinical case. Sharouni H., Narayanan P. Iranian Red Crescent Medical Center, 2015, January; 17(1): e17104.;
5. Ferry F.F. *Ferry Clinical Consultant 2016: 5 books in 1.* 1. Philadelphia: Elsevier Health Sciences; 2015, pp. 1133–1133;
6. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. Occurrence of mucormycosis associated with COVID-19: analysis of cases from 18 countries;

7. Kontoyannis D.P., Lewis R.E. How do I treat mucormycosis. *Blood*. 2011; 118: 1216–24.;
8. Lionakis M.S., Kontoyannis D.P. Glucocorticoids and invasive fungal infections. *Lancet*. 2003; 362: 1828–38.;
9. Lodigiani K., Yapticino G., Ferrazzi P., Sebastian T., Kucher N., Studt J.-D. Venous and arterial thromboembolic complications in COVID-19 patients admitted to the academic hospital in Milan, Italy. *Thromb Res*. 2020; 191: 9–14.;
10. Ophthalmic and facial veins are not valveless. Zhang J, Stringer, MD *Clin Exp Ophthalmol*. 2010 Jul; 38(5): 502-10.;
11. Patel A, Kaur H, Zess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, treatment and outcomes of mucormycosis in India. *Clin Microbiol Infect*. 2020; 26 : 944 - e9.;
12. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. *JFungi*. 2019; 5 : 26.;
13. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Cerebral vein and dural sinus thrombosis study (ISCVT). Ferro JM, Kanhao P, Stam J, Busser MG, Barinagarrementeria F, ISCVT Researchers. *Iron*. 2004 Mar; 35(3): 664-70;
14. Rawson T.M., Moore L.S., Zhu N., Ranganathan N., Skolimovska K., Gilchrist M. et al. Bacterial and fungal coinfection in people with coronavirus: a rapid review in support of COVID-19 antimicrobial prescribing. *nineteen. Clin Infect*
15. Roden M.M., Zautis T.E., Buchanan V.L., Knudsen T.A., Sarkisova T.A., Shaufele R.L. et al. Epidemiology and outcomes of zygomycosis: a review of 929 reported cases. *Clin Infect Dis*. 2005; 41: 634–53.; *Dis*. 2020; 71: 2459–68.;
16. Septic thrombosis of the cavernous sinuses. DiNubile MJ *Arch Neurol*. May 1988; 45(5): 567-72;
17. Septic cavernous sinus thrombosis: two different mechanisms. Pavlovich P, Looi A, Rutman J. *Orbita*. 2006 Mar; 25(1): 39-43;
18. Singh A.K., Singh R., Joshi S.R., Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. *Diabetes Syndrome*. 2021 doi: 10.1016/j.dsx. 2021.05.019.;
19. Song G, Liang G, Liu W. Co-occurring fungal infections associated with the global COVID-19 pandemic: a clinical and diagnostic perspective from China. *Mycopathology*. 2020; 31:1–8.;
20. Spectrum of cavernous sinus and orbital vein thrombosis: a case and review. Lai PF, Kushimano, MD *Skull Base Surg*. 1996; 6(1):53-9.;

21. Sylvie, Colani S, Huari N, Halua M, Alawi Lamrani Y, Bubbow M. Spontaneous pneumomediastinum occurring in SARS-COV-2 infection. *ID Cases*. 2020; 21: e00806.;
22. Visualization of cerebral vein thrombosis: modern methods, range of results and diagnostic errors. Leach J.L., Fortuna R.B., Jones B.V., Gaskill-Shipley M.F. *Radiography*. 2006 Oct; 26 Supplement 1 (): S19-41; discussion of S42-3.